Compare MasTec Inc (MTZ) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Zoetis Inc — how do they compare? MasTec Inc trades at $280.16 (market cap $21.90B), while Zoetis Inc trades at $73.7 (market cap $31.14B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays a 2.81% dividend while MasTec Inc pays none. Which is the better fit depends on your goals.
| MTZ | ZTS | |
|---|---|---|
Market Cap | $21.90B | $31.14B |
Sector | Technology | Health |
52-Week High | $437.51 | $156.76 |
52-Week Low | $172.51 | $71.91 |
Enterprise Value | $24.81B | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $281.11, up 4.78% over 24 hours, amid strong 2026 performance with record Q2 revenue of $4.37 billion and a $21.4 billion backlog. Technical indicators show a bearish trend with resistance near $283, while fundamentals reflect robust growth—40% EBITDA growth in Q2—though valuation multiples like a P/E of 43.42 suggest premium pricing. Recent news highlights the acquisition of The Superior Group and a $650 million senior notes offering, bolstering infrastructure capabilities.
The outlook is positive, driven by infrastructure demand and raised 2026 guidance, but risks include execution challenges from acquisitions and communications segment delays. Analysts are overwhelmingly bullish with an 88.89% buy rating and a $439.56 consensus target, implying significant upside from current levels.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
